

Update on Veronate

Chief Medical Officer, VP Clinical Development Seth Hetherington, M.D. Inhibitex, Inc.

Veronate®

- Plasma-derived, donor-selected polyclonal IVIG
- High levels of IgG directed against staphylococcal proteins (MSCRAMM®)
- S. aureus ClfA
- S. epidermidis SdrG
- Formulated for premature infants
- 0.2% NaCl
- No sucrose
- No preservative



Veronate® – Target Indication

- Premature infants, 500 to 1250 grams
- Prevention of nosocomial infections due to:
- S. aureus
- S. epidermidis
- Other potential benefits
- Reduction in candidemia
- Reduce overall mortality




Pre-Clinical Studies

- Reduced mortality from S. epidermidis infection in 3-6 day old rats D
- tissue invasion in *prophylaxis* rabbit endocarditis model Reduced S. aureus and S. epidermidis bacteremia and
- epidermidis in **treatment** of endocarditis in rabbit model Reduced tissue invasion by both S. aureus and S.




Veronate Prevents S. epidermidis Mediated Mortality in a Suckling Rat Model






epidermidis Infection in a Rabbit Model of Veronate Reduces the Incidence of S. Infectious Endocarditis



Veronate Reduces the Incidence of S. aureus Infection in a Rabbit Model of Infectious Endocarditis





Summary of Phase II Results

- Veronate was well tolerated
- 1,280 doses administered
- No significant difference in AE's or SAE's between placebo and treatment groups
- 750 mg/kg dose selected for pivotal Phase III trial •
- Relative reductions between placebo and 750 mg/kg treatment cohorts on an intent-to-treat basis: O
- S. aureus infections 63%
- Fungal infections 67%
- All-cause mortality 36%



Summary of the Trends in Phase II

- Magnitude of the observed differences in infection rates ~60%
- Differences observed at the highest dose tested
- Dose-response by time-to-onset analysis
- Differences for the Veronate targeted organisms
- Lack of effect on non-targeted organisms
- Biologically plausible link to Candida spp

